<DOC>
	<DOC>NCT00225862</DOC>
	<brief_summary>A 12-week clinical research study to evaluate the tolerability, efficacy and safety of ropinirole compared to placebo(an inactive sugar pill) in the treatment of patients with RLS in the United States.</brief_summary>
	<brief_title>A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Ã‚ Inclusion criteria: Patients diagnosed with Restless Legs Syndrome (RLS). Patients diagnosed with RLS (symptoms include an overwhelming urge to move legs usually accompanied by uncomfortable sensations in the legs; usually occur at rest; worse during the evening or night and generally relieved, at least temporarily, by movement). Patients must give written informed consent prior to any specific study procedures. Exclusion criteria: Patients with a primary sleep disorder other than RLS. Patients with symptoms of secondary RLS (i.e., renal failure, iron deficient anemia, pregnancy) or other movement disorders (i.e., Parkinson's Disease). Other inclusion or exclusion criteria to be evaluated by the physician.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>RLS</keyword>
	<keyword>Restless Legs Syndrome</keyword>
</DOC>